Introduction
Burkitt's lymphoma (BL) is the most frequent non-Hodgkin's lymphoma (NHL) of childhood. 1 Genetically, it is characterized by the presence of chromosomal translocations involving the MYC gene on chromosome 8 and the immunoglobulin (Ig) heavy-or light-chain genes on chromosome 14, 22 or 2. 2 The most common translocation, accounting for 70-75% of the total, is the t(8;14)(q24;q32) in which the MYC gene is juxtaposed to the immunoglobulin heavy chain (IgH) locus on chromosome 14 in divergent orientation. The breakpoint locations vary depending on the geographic distribution of the tumor and probably on the presence or absence of Epstein-Barr virus (EBV) genome. 3 In the sporadic (Caucasian) BL, the breakpoints are usually located within exon 1 or intron 1 of the MYC gene and in the switch regions within the IgH locus. The MYC/IgH rearrangement is detectable only at the genomic DNA level, because no fusion transcript originates from the chromosomal translocation. We have recently established a long-distance polymerase chain reaction (LD-PCR) assay for the detection of the t(8;14)(q24;q32) which relies on the use of one primer specific for MYC exon 2 combined, in different reactions, with four primers for the IgH locus: three for the constant regions Cm, Cg and Ca, and one for the joining region (JH). [4] [5] The LD-PCR assay is useful not only for the molecular characterization of the tumors, but because the LD-PCR product detecting the t(8;14) is specific for each individual tumor, it represents a marker that can be used to detect micrometastases at diagnosis and to monitor minimal residual disease (MRD) in patients with disseminated BL.
Although current high-dose-intensity chemotherapy regimens combined with stratification of patients in different risk groups based on stage, surgical resection and LDH levels can obtain clinical complete remissions in the great majority of patients with BL, little is known on the prevalence of minimal disseminated disease (MDD) at diagnosis, on its response kinetics to treatment and on its possible prognostic value in BL patients.
The aim of this study was to evaluate prospectively the prevalence of minimal BM infiltration at diagnosis and the response kinetics to treatment of MRD in a series of children affected by BL enrolled in the AIEOP97-LNH clinical trial.
Materials and methods

Patients and specimens
Excess fresh tumor tissue of diagnostic biopsies from children affected by BL enrolled in the AIEOP97 protocol for NHL was selected by the local pathologist, maintained in culture medium and received in our laboratory within 24 h from biopsy. Tissue was frozen and stored at À801C until used. As per protocol, bilateral bone marrow (BM) aspirates in sodium citrate were obtained from each patient at diagnosis and, if positive for neoplastic infiltration, at day 6 (end of prephase), before the second cycle of chemotherapy and at the end of treatment. BM biopsy was also performed at diagnosis. Only morphology was a parameter for defining stage of disease. Patients were treated according to the protocol AIEOP97 for the diagnosis and therapy of B-cell NHL, based on a slightly modified BFM90 strategy: 6 after 6 days treatment with corticosteroids and low-dose cyclophosphamide (prephase), five to six 5-day cycles of highdose-intensity chemotherapy were administered to patients with advanced stage disease, whereas 2-4 cycles of less intensive chemotherapy were given in cases of localized disease. Stage IV was defined as morphological BM involvement and/or CNS involvement, whereas LD-PCR results were not used for staging.
In all of the cases, histologic and immunohistochemical diagnosis was centrally reviewed. Tumors were classified as typical BLs or atypical 'Burkitt-like' lymphomas based on morphologic and immunophenotypical features according to WHO guidelines. They were differentiated from precursor (lymphoblastic) B-cell lymphomas because of a mature B phenotype (TdTÀ, CD79a+, CD20+); in addition, they were mostly positive for CD10, Bcl-6 and negative for Bcl-2 and almost all the neoplastic cells expressed the Ki-67 antigen, as demonstrated by the nuclear positivity for Mib1. The distinction between the two subtypes of BLs and other mature Bcell lymphomas relied on careful evaluation of both immunophenotypic and morphologic features (cytoplasmic basophilia, typical chromatin pattern, starry sky pattern, mitotic activity, etc).
DNA extraction
From each BM sample, nucleated cells were isolated by differential lysis and subsequently processed for DNA extraction. Bioptic material was thawed, incubated overnight at 561C with proteinase K solution and subsequently high molecular weight genomic DNA was prepared using the QIAamp Tissue kit (Qiagen, Hilden, Germany), following the manufacturer's instructions.
LD-PCR
Detailed information on the assay was published previously. 4 Briefly, we used one primer for the MYC gene (MYC/04) combined alternatively with one of four primers for the IgH locus: three primers for the constant regions (Cm/03, Cg/02, Ca/ 01) and one for the joining region (JH). 4 Quality of genomic DNA was assessed in each case by using a combination of primers of the Human tPA Control Primer set (Roche Diagnostics, Milan, Italy). Each reaction mixture (50 ml) contained 250 ng of DNA, 60 pmol of each primer, and amounts of dNTPs, buffer III, oligonucleotides, and a mix of Taq and Pwo polymerases (Expand Long template PCR System, Roche Diagnostics), as suggested by the manufacturer. PCR was performed in a Perkin-Elmer Thermal Cycler 9700, using cycle characteristics previously described, 4 except for an increase of total cycle number from 30 to 40 and addition of 1.5 U of Taq polymerase after the first 30 cycles. PCR products were analyzed by agarose gel electrophoresis and visualized under UV illumination after ethidium bromide staining.
The sensitivity of the assay was determined by limiting dilutions of t(8;14)-positive BL41 Burkitt cells (a gift of Dr Dolcetti, CRO, Aviano, Italy) in translocation negative Jurkat leukemia cells (ATCC, Manassas, VA, USA).
Results and discussion
Minimal disseminated disease
With the aim of studying MDD and MRD in BL, we ascertained whether LD-PCR for t(8;14) had sufficient sensitivity. Increasing dilutions of the translocation-positive BL41 cells in Jurkat leukemic cells showed a sensitivity of 10 À4 after agarose gel electrophoresis of the PCR products and ethidium bromide staining ( Figure 1) .
Detection of one tumor cell in ten thousand represents a significant sensitivity for MRD studies in BL, where other techniques, including flow cytometric analysis, cannot rely on highly sensitive tumor-specific markers or if they do, the sensitivity is lower, as in the case of Southern blot or FISH analyses. 7, 8, 9 Tumor specimens from 78 consecutive children with BL enroled in the AIEOP97 protocol were assayed for t(8;14)(q24;q32) by LD-PCR. DNAs extracted from all of the samples were suitable for LD-PCR analysis because amplification of 4.8-15 kb fragments of the tPA gene was achieved in each case. In all, 52 cases (67%) were positive for the t(8;14)(q24;q32) by LD-PCR. For 33 of these patients, we obtained the BM at diagnosis and, thus, we could study MDD (Table 1 ). In 12/33 patients, BM was positive by LD-PCR, whereas only four were positive at the standard microscopic and immunophenotypic analyses.
The likelihood that BM be infiltrated in solid tumors is associated with a number of clinical variables such as tumor type and stage of disease. In general, the higher the stage of the tumor, the more likely the BM is to be involved. In our series of pediatric BL, all the patients with positive BM at diagnosis, as defined by LD-PCR positivity, had advanced stage disease.
It is also recognized that serum LDH level is an independent prognostic factor in BL, in that higher levels are associated to advanced stage disease and to a less favorable outcome. 6, 10, 11 Based on this observation, we assessed whether MDD positivity at diagnosis were associated to high levels of LDH. As shown in Table 1 , 11/12 BM-positive patients had LDH above 1000 U/l, whereas only 8/21 patients with negative BM had an LDH value higher than 1000 U/l (P ¼ 0.0036 according to the two-tailed Fisher exact test). We also determined whether a negative BM status at diagnosis, defined by a negative LD-PCR, was associated to a better probability of maintaining a CR status. Two children among the 12 BM-positive patients had a progression of disease and eventually died, whereas none of the 21 BM-negative patients showed disease progression (P ¼ 0.011, by the one-tailed Z test), suggesting that a positive MDD might have a negative prognostic impact on the outcome, although a larger series of patients is needed to evaluate this hypothesis in a multivariate analysis.
Minimal residual disease and response kinetics to treatment
The term 'complete remission' encompasses different clinical situations including complete eradication of the tumor clone, long-term persistence of tumor cells with no tendency to relapse and presence of residual tumor cells with potential evolution toward a relapse during the subsequent follow-up period. While conventional approaches are unable to discriminate among PCR detection of MRD in Burkitt's lymphoma L Mussolin et al these situations, sequential analysis of MRD has provided novel insights on the behavior of the residual neoplastic cell population and allowed the identification of different prognostic subgroups in different tumor models, including NHL. 9 Studies with the longest follow-up period have been performed not only in follicular lymphoma (FCL) patients, 12 but also in mantle cell lymphomas and small lymphocytic lymphoma/chronic lymphocytic leukemia patients. 13, 14 Almost no molecular data, however, are available on MRD in BL.
We conducted a study of MRD and determined the response kinetics to treatment in 10/12 patients with BM involvement at diagnosis. BM aspirates were obtained after the first week of treatment (prephase), before the II cycle of chemotherapy and at stop therapy ( Figure 2 ).
As shown in Figure 2 , most of the patients maintained a molecular positivity after the prephase, suggesting that 5 days of cortisone and low-dose cyclophosphamide were not sufficient for complete eradication of MDD, whereas after the first chemotherapy cycle, all patients, except two, turned negative (cases 5 and 8; Figures 2 and 3) . Another child reached only a temporary molecular complete remission (case no. 1). Of the three patients, two reached only a partial remission in extramedullary sites and died of disease progression. The patient who reached a negative BM status at stop therapy, obtained a late complete remission and is free of disease with 1-year follow-up.
Taken together these data raise the question of whether a late or absent clearance of MRD, possibly associated to a partial response in extramedullary sites, rather than BM involvement at diagnosis, may be associated with a poor outcome in BL.
Role of LD-PCR in the detection of BM involvement
Another aspect we focused on was the role of LD-PCR in assessing MDD compared to bone biopsy and BM aspirate in BL. BM biopsy provides important information on marrow cellularity and architecture in most solid tumors with tendency to BM dissemination, and is superior for the evaluation of tumor infiltration compared to BM aspirate. On the other hand, BM aspirates and smears provide better morphologic evaluation of individual hematopoietic elements, allow the quantification of different cell types, and provide fresh, unfixed cells for cytochemical staining, cytogenetic studies and molecular analysis. 15 Investigators working primarily with adult NHL patients have emphasized the superiority of BM biopsy over aspiration. The literature on childhood NHLs is rather inconsistent: some investigators believe that BM aspiration is adequate for the diagnosis of marrow involvement in young patients, but others recommend a more extensive staging, including bilateral BM biopsies and bilateral aspirates. [15] [16] [17] [18] [19] As shown in Table 1 , all the patients with negative BM aspirate by LD-PCR had a negative bone biopsy, but six patients with a negative bone biopsy were positive at the molecular analysis. One of them died of disease and one had a slow molecular response to treatment. These findings suggest that in t(8;14)-positive BL patients, LD-PCR is more sensitive that BM biopsy, which in our series, as in others' experience, was more sensitive than BM aspirate.
In our hands, LD-PCR was also critical in excluding falsepositive BM involvement. The microscopic examination of BM smears in four patients demonstrated the presence of a limited number of blasts without typical L3 features (patients 24 and 30, classified as stage III) or with a morphology compatible with disease dissemination (patients 21 and 31, classified as stages IV), but the negativity of LD-PCR allowed us to exclude BM involvement. In one patient (patient no. 6), the morphological study of BM was not achieved because of the extremely low number of nucleated cells, but the LD-PCR assay was positive. These different situations support the role of the LD-PCR for the t(8;14) in discriminating doubtful MDD conditions.
Conclusions
In conclusion, we demonstrated that the LD-PCR for the MYC/ IgH rearrangement in BL can be used for MDD and MRD studies, being more sensitive and more specific than other assays currently used, and suggest that its application might have clinical relevance in the management of childhood BL. Its implementation in larger prospective clinical trials would contribute to clarify the role of MRD in BL and ultimately might help clinicians in the identification of a subgroup of patients who may benefit from alternative or complementary therapeutic approaches to the current successful high dose-intensive treatments. Given the reasonable cost and the feasibility of the t(8;14) LD-PCR approach to BL, both for MRD survey during standard treatment and to monitor hematopoietic progenitor harvests in the context of an intensification program, we plan to extend this study to the future AIEOP protocols for B-cell NHL and hope it coud be extended to other collaborative groups. 
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Figure 2
Minimal residual disease response kinetics in BL patients. A series of 10 patients with BM involvement at diagnosis (patients 1-10 from Table 1 ), determined by LD-PCR, were studied at subsequent time points, including the end of prephase (day 6), at hematological recovery after the first cycle of chemotherapy, and at stop therapy. The + and À signs refer to positive or negative MRD in BM, by LD-PCR; ++ signifies that BM was positive both morphologically and by LD-PCR. Six out of 10 patients remained positive after the prephase, whereas only two of them were positive after the first cycle of chemotherapy, remained positive at stop therapy and finally died of disease. Pts ¼ patients. n.a.=not available. 
Figure 3
Characteristic pattern of MRD kinetics in a child with BL. The t(8;14) LD-PCR product was detected in BL cells from pleural effusion (PE) and in the BM aspirate at diagnosis (BM0), which was negative by microscopic examination of both BM smear and BM biopsy; BM was still positive after the prephase (BM1), but not after the first chemotherapy cycle (BM2) and at stop therapy (BM3). The t(8;14)-negative SU-DHL-1 anaplastic lymphoma cell line and positive BL41 Burkitt's cell line were used as negative and positive controls, respectively. Marker sizes are indicated on the left.
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